Leveraging advanced analytical tools to de-risk pharmaceutical development

Leveraging advanced analytical tools to de-risk pharmaceutical development

Brought to you by Lonza Small Molecules

Overview

Drug development continues to advance understanding about causes of disease as well as to innovate therapeutic modalities. Yet the process remains time intensive, costly, and high risk. The average drug takes over 10 years and $1 billion–$2 billion to be approved for clinical use— yet 90% of new drugs reaching Phase I clinic al trials ultimately fail to reach approval.

This high risk of failure, along with the substantial investment of time, labor, and financial resources put into every new drug candidate, poses a persistent challenge for drug developers. To ensure the efficient use of development resources and the creation of safe, effective, and reliable products for patients, drugmakers must take steps to de-risk development at every step. In this e-book, learn about three tools that drug developers can use to successfully navigate the journey from candidate compound to clinical success.

Key Objectives:

How solid form screening is useful at development stages from lead form identification to intellectual property protection
How physiologically based pharmacokinetic (PBPK) modeling provides a deeper view into how a drug behaves in the body while accounting for patient variability
How including real word supply chain information in a retrosynthetic analysis can deliver synthetic routes with reduced cost and risk

Brought to you by:

Please complete the form to download the eBook.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country*

Business Phone*

Do you currently have an early phase project in development?*

What is your biggest drug development challenge?

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.